Bevacizumab [Avastin]: Process for Removal of Breast Cancer Indication Begun Because of Lack of Efficacy
December 16, 2010 – Today, the American Food and Drug Administration notified healthcare professionals and patients that it is recommending removing the breast cancer indication for Bevacizumab [Avastin] because the drug has not been shown to be safe and effective …